New drug for advanced skin lymphoma that stopped responding to treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new investigational drug (DT-7012) for people with a type of skin lymphoma that hasn't responded to standard treatments. The drug is given as an infusion and aims to boost your immune system to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a diagnosis of mycosis fungoides or Sézary syndrome (types of skin lymphoma).
- Your lymphoma must be stage IB to IVB (spread beyond the skin or more advanced).
- You must have tried at least two prior treatments and they didn't work.
- You should be generally active (able to do light work or self-care).
- Your liver, kidney, and blood counts need to be within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
This trial tests whether giving a drug called brentuximab vedotin after a stem cell transplant can help keep your lymphoma in check and prevent it from coming back. It is for people with a specific type of lymphoma (mycosis fungoides) that has been hard to treat and who have recently had a transplant.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.